Clinical Trial: A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT(R)(Dupilumab) in Healthy Chinese Volunteers

U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07502534) titled 'A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT(R)(Dupilumab) in Healthy Chinese Volunteers' on March 26.

Brief Summary: This study is a multicenter, randomized, double-masked, parallel-group, reference-drug-controlled clinical trial of IBI3027 in healthy male volunteers.

Healthy volunteers will be randomly assigned in a 1:1 ratio to receive either IBI3027 or DUPIXENT?. The dosage for both groups is 300 mg. The entire study includes a 28-day screening period and a 56-day observation period (including 3 days of hospitalization). Randomization is stratified by body weight at baseline (D1) ≤ 70 kg vs. > 70 ...